rs2234714 — ABCG1 ABCG1 promoter variant

ABCG1 Promoter — A Tagging Variant in the Cholesterol Efflux Locus

ABCG1 (ATP-binding cassette transporter G1¹¹ ATP-binding cassette transporter G1
a membrane protein that pumps cholesterol from macrophages and other peripheral cells onto HDL particles in the bloodstream) is one of two key transporters that drive reverse cholesterol transport — the pathway that clears excess cholesterol from arterial walls and returns it to the liver for disposal. rs2234714 sits in an intronic region of the ABCG1 gene approximately 768 base pairs upstream of a transcribed region, tagging the same chromosomal segment as other ABCG1 promoter variants that have been linked to coronary artery disease (CAD) susceptibility.

The variant does not appear to alter ABCG1 transcription directly — a luciferase reporter assay found no functional effect from this specific position. Its CAD association is therefore most likely due to linkage disequilibrium²² linkage disequilibrium
the non-random co-inheritance of nearby alleles, so that rs2234714 tracks alongside a functionally important nearby variant without itself causing the effect with functionally relevant variants at the ABCG1 promoter locus, particularly rs57137919 (-367G>A).

The Mechanism

ABCG1 acts as the second-wave transporter in the two-step cholesterol efflux relay. ABCA1³³ ABCA1
ATP-binding cassette transporter A1, which initiates reverse cholesterol transport by loading nascent HDL particles starts the process by attaching cholesterol and phospholipids to lipid-poor apolipoprotein A-I. ABCG1 then continues the relay, pumping additional cholesterol onto these maturing HDL particles and enabling them to carry larger cholesterol loads back to the liver.

A functional study of the nearby rs57137919 promoter variant⁴⁴ functional study of the nearby rs57137919 promoter variant
Liu et al. ABCG1 rs57137919G>A polymorphism is functionally associated with varying gene expression and apoptosis of macrophages. PLoS One, 2014 demonstrated that reduced ABCG1 expression at this locus causes approximately 23% less cholesterol efflux to HDL in macrophages and a 2-fold increase in apoptosis of cholesterol-loaded macrophages — hallmarks of impaired plaque clearance. While rs2234714 did not show the same functional signal in reporter assays, it resides on the same genomic segment and tracks alongside this biologically meaningful variation.

Beyond lipid transport, ABCG1 also suppresses the NLRP3 inflammasome⁵⁵ ABCG1 also suppresses the NLRP3 inflammasome
Westerterp et al. Cholesterol Efflux Pathways Suppress Inflammasome Activation, NETosis, and Atherogenesis. Circulation, 2018 in macrophages and monocytes. When cholesterol efflux is impaired, intracellular cholesterol accumulation triggers inflammatory cytokine release (IL-1β, IL-18) independently of circulating HDL-C — meaning ABCG1 variants can raise cardiovascular risk through inflammation, not just through lipid channels.

The Evidence

The primary association study⁶⁶ primary association study
Xu et al. A polymorphism in the ABCG1 promoter is functionally associated with coronary artery disease in a Chinese Han population. Atherosclerosis, 2011 enrolled 1,021 CAD patients and 1,013 controls from a Han Chinese cohort. The rs2234714 A allele was associated with reduced CAD risk in a recessive model (adjusted OR 0.64, p = 0.015), meaning AA homozygotes had approximately 36% lower odds of CAD compared to G-allele carriers. Importantly, the authors found no functional effect of this specific variant in promoter reporter assays, suggesting the association is driven by LD with the functionally active rs57137919 variant rather than by rs2234714 itself.

The evidence is currently limited to this single study in one population. No large European GWAS or replication cohort has independently confirmed the rs2234714 CAD signal. This places the evidence at the emerging level until replicated in independent populations.

A comprehensive pharmacological review⁷⁷ comprehensive pharmacological review
Frambach et al. Brothers in Arms: ABCA1- and ABCG1-Mediated Cholesterol Efflux as Promising Targets in Cardiovascular Disease Treatment. Pharmacol Rev, 2020 reinforces the broader biological relevance of the ABCG1 locus: reduced transporter expression is rate-limiting for reverse cholesterol transport, and pharmacological enhancement of ABCG1 activity is an active therapeutic research direction for atherosclerosis prevention.

Practical Actions

Because rs2234714 is likely a tagging variant, its most actionable implication is that G-allele homozygotes may carry a slightly higher burden of risk variants at the ABCG1 promoter locus. Supporting ABCG1-mediated cholesterol efflux through dietary and lifestyle approaches has the same mechanistic rationale here as for other ABCG1 variants. Omega-3 fatty acids (EPA/DHA) upregulate ABCG1 expression in macrophages through PPAR-gamma and LXR signaling pathways. Monitoring HDL-C as a surrogate for reverse cholesterol transport efficiency is warranted for GG homozygotes.

Interactions

rs2234714 lies on the same ABCG1 haplotype block as rs1044317 (3'UTR regulatory variant) and rs57137919 (promoter variant with documented functional effects on expression and macrophage cholesterol efflux). Individuals carrying risk haplotypes spanning multiple ABCG1 variants may have greater cumulative impairment of cholesterol efflux than any single variant predicts. ABCA1 variants (rs2853579, rs4149268) affect the first step of the same cholesterol efflux relay, and compound effects across the ABCA1–ABCG1 pathway are biologically plausible.